Exhibit 32.1
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the quarterly report of Emmaus Life Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Willis C. Lee |
|
Willis C. Lee |
|
Co-President and Chief Operating Officer |
|
(Principal Executive Officer) |
|
November 13, 2023 |
|
|
|
/s/ George Sekulich |
|
Co-President and Chief Commercial Officer |
|
(Principal Executive Officer) |
|
November 13, 2023 |
|
|
|
/s/ Yasushi Nagasaki |
|
Yasushi Nagasaki |
|
Chief Financial Officer |
|
(Principal Financial and Accounting Officer) |
|
November 13, 2023 |
|